What are the best treatments for Progressive Supranuclear Palsy?

Currently, there is no cure for Progressive Supranuclear Palsy (PSP), so treatment focuses on managing symptoms through a combination of pharmacological, rehabilitative, and supportive care strategies tailored to the individual.

Pharmacological Management

While no medication can halt the progression of Progressive Supranuclear Palsy, physicians may prescribe agents to address specific symptoms. Levodopa (Sinemet) is sometimes trialed to address parkinsonism, though the response in patients with PSP is typically modest and short-lived compared to those with Parkinson’s disease. Other medications, such as antidepressants (e.g., amitriptyline or selective serotonin reuptake inhibitors), may be used to manage mood changes or pseudobulbar affect. Because Progressive Supranuclear Palsy involves complex neurological changes, all medication trials must be closely monitored by a neurologist to balance symptom relief against potential side effects like confusion or orthostatic hypotension.

Non-Pharmacological and Supportive Care

Rehabilitative therapies are the cornerstone of care for Progressive Supranuclear Palsy. Physical therapy is essential to improve balance and prevent falls, which are a hallmark of the condition. Occupational therapy helps adapt the home environment to ensure safety, while speech-language pathology is vital for addressing slurred speech and the progressive difficulty with swallowing (dysphagia). As the disease advances, nutritional support through modified diets or, in some cases, a feeding tube, may be necessary to maintain weight and prevent aspiration pneumonia.

Multidisciplinary Care Team

Managing Progressive Supranuclear Palsy requires a coordinated team approach. Your core team should include a movement disorder neurologist, a physical therapist, an occupational therapist, a speech-language pathologist, and a social worker or counselor to support both the patient and the caregiver. Emerging research and clinical trials are actively investigating tau-targeting therapies, though these remain experimental and are not yet part of standard clinical practice.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Treatment for Progressive Supranuclear Palsy must be personalized by your medical team; please consult with your neurologist before making any changes to your care plan.

References

• CurePSP (Foundation for PSP/CBD and Related Brain Diseases)


• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: Progressive Supranuclear Palsy